Eli Lilly and Company (LLY): modelo de negócios [Jan-2025 Atualizado]

No cenário dinâmico da inovação farmacêutica, a Eli Lilly e a Company se destaca como um farol de soluções transformadoras de saúde, elaborando meticulosamente sua estratégia de negócios por meio de uma abrangente modelo de tela que entrelaça pesquisas de ponta, abordagens centradas no paciente e parcerias globais de assistência médica. Desde tratamentos inovadores para diabetes até intervenções inovadoras de oncologia, o modelo de Lilly representa um projeto sofisticado de como os gigantes farmacêuticos modernos navegam em desafios médicos complexos, impulsionam a descoberta científica e oferecem terapias que mudam a vida aos pacientes em todo o mundo.

Eli Lilly and Company (LLY) - Modelo de Negócios: Principais Parcerias

Alianças estratégicas com instituições de pesquisa acadêmica

Eli Lilly estabeleceu parcerias com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco em parceria	Ano estabelecido
Universidade de Indiana	Pesquisa em neurociência	2019
Universidade da Califórnia, São Francisco	Desenvolvimento de medicamentos para oncologia	2021
Escola de Medicina de Harvard	Pesquisa em diabetes	2020

Acordos colaborativos de desenvolvimento de medicamentos com empresas de biotecnologia

As principais parcerias de colaboração de biotecnologia incluem:

• Incyte Corporation: Pagamento inicial de US $ 150 milhões para colaboração de inibidores da JAK
• Ciências da vida em verdade: Plataforma de gerenciamento de diabetes conjuntos de US $ 500 milhões
• ABCELLERA BIOLOGICICO: US $ 45 milhões em parceria de descoberta de anticorpos

Cadeia de suprimentos farmacêuticos e parceiros de distribuição

Parceiro	Serviço	Valor do contrato
McKesson Corporation	Distribuição farmacêutica	Contrato anual de US $ 1,2 bilhão
Amerisourcebergen	Gerenciamento global da cadeia de suprimentos	Contrato anual de US $ 850 milhões

Organizações de fabricação contratadas

Parcerias de fabricação contratadas de Eli Lilly:

• Lonza Group: contrato de fabricação de biológicos de US $ 300 milhões
• Boehringer Ingelheim: US $ 250 milhões de colaboração de fabricação
• Samsung Biologics: Contrato de produção de vacinas de US $ 180 milhões

Tecnologia global de saúde e empresas de saúde digital

Parceiro	Foco em tecnologia	Investimento
Google Health	Diagnósticos médicos orientados a IA	US $ 200 milhões de investimento estratégico
Maçã	Monitoramento da saúde digital	Colaboração de US $ 75 milhões
Teladoc Health	Integração da plataforma de telessaúde	Parceria de US $ 120 milhões

Eli Lilly and Company (LLY) - Modelo de Negócios: Atividades -chave

Pesquisa e Desenvolvimento Farmacêutico

Investimento de P&D: US $ 7,1 bilhões em 2023

Métrica de P&D	2023 dados
Despesas totais de P&D	US $ 7,1 bilhões
Pessoal de P&D	6.800 pesquisadores
Novas aplicações de drogas	5 submissões principais

Gerenciamento de ensaios clínicos

Ensaios clínicos Portfólio: 175 ensaios clínicos ativos em 2023

• Locais globais de ensaios clínicos: 45 países
• Inscrição do paciente: 62.000 participantes
• Fases de teste: Fase I-IV em várias áreas terapêuticas

Descoberta e inovação de drogas

Métrica de inovação	2023 desempenho
Novas entidades moleculares	3 terapias inovadoras
Aplicações de patentes	127 novos registros de patentes
Colaborações de pesquisa	22 parcerias acadêmicas e do setor

Conformidade regulatória e teste clínico

Orçamento de conformidade regulatória: US $ 450 milhões em 2023

• Interações da FDA: 48 reuniões formais
• Departamentos de conformidade: 350 profissionais dedicados
• Taxa de sucesso de submissão regulatória: 92%

Marketing global e comercialização de produtos

Métrica de marketing	2023 dados
Gastos globais de marketing	US $ 3,2 bilhões
Mercados de lançamento de produtos	38 países
Tamanho da força de vendas	7.500 representantes

Eli Lilly and Company (Lly) - Modelo de Negócios: Recursos -Principais

Instalações avançadas de pesquisa e desenvolvimento

Eli Lilly opera vários centros de pesquisa em todo o mundo, com instalações -chave, incluindo:

Localização	Foco na pesquisa	Tamanho (Sq. Ft.)
Indianapolis, IN	Neurociência e oncologia	1,2 milhão
San Diego, CA.	Pesquisa de biotecnologia	750,000
Centro de Pesquisa da China	Mercados emergentes inovação	350,000

Portfólio de propriedade intelectual

Estatísticas de propriedade intelectual de Eli Lilly:

• Total de patentes ativas: 5.672
• Investimento de P&D em 2023: US $ 2,98 bilhões
• Duração da proteção de patentes: média de 15 a 20 anos

Força de trabalho científica e médica altamente qualificada

Categoria de funcionários	Número de funcionários	Porcentagem com graus avançados
Força de trabalho total	38,400	N / D
Cientistas de pesquisa	4,650	92%
Pesquisadores de doutorado	1,890	100%

Capital financeiro substancial para inovação

Recursos Financeiros a partir do quarto trimestre 2023:

• Caixa e investimentos totais: US $ 7,6 bilhões
• Orçamento anual de P&D: US $ 2,98 bilhões
• Capitalização de mercado: US $ 363,4 bilhões

Extensa infraestrutura de fabricação global

Local de fabricação	Capacidade de produção	Principais linhas de produtos
Indianapolis, IN	35% da produção global	Diabetes, oncologia
Porto Rico	25% da produção global	Medicamentos de neurociência
Instalação de fabricação da China	15% da produção global	Medicamentos de mercado emergentes

Eli Lilly and Company (LLY) - Modelo de Negócios: Proposições de Valor

Soluções farmacêuticas inovadoras para condições médicas complexas

O portfólio farmacêutico de Eli Lilly em 2024 inclui áreas terapêuticas -chave com desempenho específico do mercado:

Área terapêutica	Receita anual (2023)	Participação de mercado global
Tratamento com diabetes	US $ 7,9 bilhões	15.3%
Soluções de oncologia	US $ 6,5 bilhões	12.7%
Intervenções de neurociência	US $ 4,2 bilhões	9.6%

Tratamentos biofarmacêuticos avançados

Os principais segmentos de tratamento biofarmacêutico incluem:

• Medicamentos para diabetes: trulicidade (receita de US $ 4,3 bilhões)
• Oncologia Medicamentos: Verzenio (receita de US $ 3,2 bilhões)
• Tratamentos de neurociência: emgalidade (receita de US $ 1,7 bilhão)

Intervenções médicas validadas clinicamente de alta qualidade e clinicamente

Métricas de validação clínica para os principais desenvolvimentos de medicamentos:

Medicamento	Taxa de sucesso do ensaio clínico	Taxa de aprovação do FDA
Medicamentos para diabetes	87.5%	92%
Tratamentos oncológicos	76.3%	85%
Drogas de neurociência	68.9%	79%

Abordagem de desenvolvimento de medicamentos centrada no paciente

Investimento de pesquisa e desenvolvimento em 2023: US $ 6,8 bilhões, representando 23,5% da receita total da empresa.

Soluções de saúde personalizadas

Redução de portfólio de medicamentos personalizados:

• Tratamentos de oncologia de precisão: US $ 2,1 bilhões
• Terapias genéticas direcionadas: US $ 1,5 bilhão
• Protocolos de tratamento individualizados: US $ 900 milhões

Eli Lilly and Company (LLY) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento profissional médico direto

Em 2023, Eli Lilly se envolveu com aproximadamente 784.000 profissionais de saúde por meio de canais de comunicação direta. A equipe de Assuntos Médicos da empresa conduziu 2.356 simpósios profissionais e eventos de educação médica.

Tipo de engajamento	Número de interações
Conferências médicas	1,247
Webinars médicos on -line	1,109
Consultas médicas individuais	5,673

Programas de apoio ao paciente e educação

A Eli Lilly investiu US $ 87,3 milhões em programas de apoio aos pacientes em 2023, cobrindo várias áreas terapêuticas.

• Programa de apoio ao paciente para diabetes: 328.000 pacientes inscritos
• Iniciativa de Educação para Pacientes Oncológicos: 156.000 participantes
• Programa de apoio à saúde mental: 214.000 indivíduos apoiados

Plataformas de saúde digital e comunidades de pacientes

As plataformas de saúde digital da empresa atingiram 1,2 milhão de usuários ativos em 2023, com um crescimento de 37% ano a ano.

Plataforma digital	Usuários ativos	Taxa de engajamento
Lilly Patient Portal	742,000	68%
Aplicativo de saúde móvel	458,000	52%

Comunicação contínua de pesquisa médica

Em 2023, Eli Lilly publicou 672 trabalhos de pesquisa revisados ​​por pares e conduziu 247 ensaios clínicos em vários domínios terapêuticos.

• Publicações de pesquisa: 672
• Ensaios clínicos: 247
• Investimento de pesquisa: US $ 6,8 bilhões

Serviços personalizados de consulta de saúde

Os Serviços de Consulta de Saúde Personalizados da Eli Lilly administraram 93.000 consultas individuais de pacientes em 2023, com uma taxa de satisfação de 94%.

Tipo de consulta	Número de consultas	Satisfação do paciente
Consultas de telessaúde	57,000	92%
Consultas especializadas pessoais	36,000	96%

Eli Lilly and Company (Lly) - Modelo de Negócios: Canais

Força de vendas direta para profissionais de saúde

A Eli Lilly mantém uma força de vendas dedicada de 6.200 representantes farmacêuticos em 2023, direcionando os prestadores de serviços de saúde nos Estados Unidos.

Categoria de força de vendas	Número de representantes	Alvo primário
Especialistas em oncologia	1,450	Oncologistas e centros de tratamento de câncer
Representantes de cuidados com diabetes	1,800	Endocrinologistas e médicos de cuidados primários
Equipe de neurociência	1,250	Psiquiatras e neurologistas

Redes de distribuidores farmacêuticos

Eli Lilly colabora com os principais distribuidores farmacêuticos para garantir uma ampla distribuição de produtos.

• McKesson Corporation - Distribuidor Primário com 85% de cobertura de instalações de saúde dos EUA
• Amerisourcebergen - lida com 65% da distribuição de rede hospitalar e de farmácia
• Cardinal Health - gerencia 55% dos canais farmacêuticos especiais

Plataformas de marketing digital

Os canais de engajamento digital representam 42% da estratégia de marketing da Eli Lilly em 2024.

Plataforma digital	Taxa de engajamento	Visitantes únicos mensais
Lillypad.com	3.7%	275,000
Profissional LinkedIn	2.9%	185,000
Webinars profissionais médicos	4.2%	95.000 participantes mensalmente

Conferências médicas e simpósios profissionais

Eli Lilly participa de 87 conferências médicas internacionais anualmente, com um orçamento de US $ 42,3 milhões para patrocínio e apresentação da conferência.

Recursos de Informação Médica Online

A empresa mantém recursos médicos on -line abrangentes com 1,2 milhão de usuários profissionais de saúde registrados.

Tipo de recurso	Base de usuários	Atualizações anuais de conteúdo
Portal de pesquisa clínica	620.000 usuários	378 novas publicações de pesquisa
Plataforma de educação profissional	420.000 usuários	245 módulos de educação médica contínua
Banco de dados de informações sobre medicamentos	160.000 usuários	512 Medicação profile Atualizações

Eli Lilly and Company (Lly) - Modelo de Negócios: Segmentos de Clientes

Profissionais de saúde

Em 2024, Eli Lilly tem como alvo aproximadamente 1,5 milhão de profissionais de saúde nos Estados Unidos.

Quebra de segmento	Número de profissionais
Oncologistas	22,500
Endocrinologistas	18,700
Neurologistas	16,300

Sistemas hospitalares

Eli Lilly atende 4.862 hospitais nos Estados Unidos em 2024.

• Grandes redes hospitalares: 672
• Hospitais comunitários: 3.190
• Centros de tratamento especializados: 1.000

Pesquisadores farmacêuticos

A empresa se envolve com aproximadamente 85.000 pesquisadores farmacêuticos em todo o mundo.

Segmento de pesquisa	Número de pesquisadores
Instituições acadêmicas	42,500
Empresas farmacêuticas	35,200
Centros de Pesquisa Governamental	7,300

Pacientes com condições médicas crônicas

Eli Lilly atende 3,2 milhões de pacientes com condições crônicas em 2024.

• Pacientes com diabetes: 1.450.000
• Pacientes com oncologia: 650.000
• Pacientes de Transtorno Neurológico: 450.000
• Pacientes com imunologia: 350.000

Instituições de Governo e Saúde Privadas

A empresa colabora com 2.300 instituições de saúde em todo o país.

Tipo de instituição	Número de instituições
Sistemas federais de saúde	412
Sistemas estaduais de saúde	876
Redes privadas de saúde	1,012

Eli Lilly and Company (Lly) - Modelo de Negócios: Estrutura de Custo

Extensas despesas de pesquisa e desenvolvimento

Em 2023, Eli Lilly investiu US $ 7,1 bilhões em despesas de pesquisa e desenvolvimento, representando aproximadamente 20,3% da receita total. O colapso de gastos com P&D da empresa inclui:

Categoria de investimento em P&D	Valor (US $ bilhão)	Percentagem
Pesquisa farmacêutica	5.2	73.2%
Desenvolvimento de Biotecnologia	1.3	18.3%
Tecnologias emergentes	0.6	8.5%

Investimentos de ensaios clínicos

As despesas de ensaios clínicos de Eli Lilly em 2023 totalizaram US $ 2,3 bilhões, com a seguinte alocação:

• Ensaios clínicos de oncologia: US $ 780 milhões
• Ensaios de pesquisa de diabetes: US $ 450 milhões
• Estudos clínicos de neurociência: US $ 350 milhões
• Ensaios de imunologia: US $ 270 milhões
• Outros ensaios da área terapêutica: US $ 450 milhões

Custos globais de fabricação e produção

As despesas de fabricação de 2023 foram de US $ 4,6 bilhões, distribuídas nas instalações globais:

Local de fabricação	Custo de produção (US $ milhões)	Porcentagem de total
Estados Unidos	2,070	45%
Europa	1,380	30%
Ásia-Pacífico	690	15%
América latina	460	10%

Infraestrutura de marketing e vendas

As despesas de marketing e vendas de 2023 totalizaram US $ 3,9 bilhões, com a seguinte distribuição:

• Custos diretos da força de vendas: US $ 1,6 bilhão
• Marketing Digital: US $ 520 milhões
• Patrocínios de Eventos Médicos e de Conferência: US $ 380 milhões
• Materiais de suporte de vendas: US $ 240 milhões
• Operações de marketing internacional: US $ 1,16 bilhão

Despesas de conformidade regulatória

Os custos de conformidade regulatória para 2023 foram de US $ 680 milhões, incluindo:

Categoria de conformidade	Despesa (US $ milhões)
Submissões regulatórias da FDA	210
Garantia de qualidade	180
Conformidade legal	150
Aprovações regulatórias internacionais	140

Eli Lilly and Company (LLY) - Modelo de negócios: fluxos de receita

Vendas de medicamentos prescritos

Receita farmacêutica total para 2023: US $ 29,4 bilhões

Principais medicamentos geradores de receita	2023 VENDAS ($ M)
Trulicidade (diabetes)	5,332
Mounjaro (diabetes/obesidade)	5,422
Taltz (imunologia)	2,302
Verzenio (oncologia)	2,191

Licenciamento de produtos farmacêuticos patenteados

Receita de licenciamento para 2023: US $ 1,2 bilhão

Distribuição farmacêutica do mercado global

Vendas farmacêuticas internacionais: US $ 12,6 bilhões em 2023

Região geográfica	Vendas ($ b)
Estados Unidos	16.8
Europa	4.9
Ásia -Pacífico	3.7

Soluções de tecnologia de saúde

Receita de saúde e tecnologia digital: US $ 456 milhões em 2023

Acordos de colaboração de pesquisa

Financiamento colaborativo de pesquisa: US $ 782 milhões em 2023

Parceiro de colaboração	Foco na pesquisa	Valor do acordo ($ m)
Boehringer Ingelheim	Diabetes/cardiovascular	350
AstraZeneca	Oncologia	250
Incyte Corporation	Imunologia	182

Eli Lilly and Company (LLY) - Canvas Business Model: Value Propositions

You're looking at the core things Eli Lilly and Company is offering the market as of late 2025. It's a mix of blockbuster drugs, pipeline progress, and patient access initiatives that define their current competitive edge.

Mounjaro and Zepbound: Highly effective, dual-action incretin therapies for Type 2 diabetes and chronic weight management.

The incretin franchise is the primary value driver. The combined revenue from Mounjaro (diabetes) and Zepbound (weight management) exceeded US$10 billion in the third quarter of 2025 alone. Mounjaro delivered US$6.5 billion in Q3 2025 revenue, marking a 109% year-over-year increase. Zepbound showed even stronger growth, bringing in US$3.6 billion, up 185% from Q3 2024. For the first half of 2025, Mounjaro sales were US$9.04 billion and Zepbound sales were US$5.69 billion. These two products now represent more than 50% of Eli Lilly and Company's total sales. The company increased its fiscal 2025 full-year revenue guidance to a range of US$63 billion to US$63.5 billion, up from an earlier target of US$60-62 billion.

Metric	Value (Q3 2025)	Context
Mounjaro Revenue	US$6.5 billion	Triple-digit growth driver for Q3 2025
Zepbound Revenue	US$3.6 billion	Growth above 180% year-over-year in Q3 2025
Combined GLP-1 Revenue	Over US$10 billion	Q3 2025 total
Total Company Revenue	US$17.6 billion	Q3 2025 total, a 54% rise from Q3 2024

Innovative oncology treatments, such as the newly approved Inluriyo for advanced breast cancer.

Eli Lilly and Company achieved a key milestone with the U.S. Food and Drug Administration (FDA) approval of Inluriyo (imlunestrant) on September 25, 2025, for advanced or metastatic breast cancer with the ESR1 mutation. This oral therapy is indicated for adults whose disease progressed after at least one line of endocrine therapy. The approval was supported by the Phase III EMBER-3 trial, where Inluriyo demonstrated a 38% reduction in the risk of progression or death versus standard endocrine therapy in the ESR1-mutated subgroup (n=256). The median Progression-Free Survival (PFS) was 5.5 months for Inluriyo compared to 3.8 months for fulvestrant or exemestane. The company maintains an impressive 82.6% gross profit margin.

• Inluriyo commercial launch planned for US in autumn 2025.
• In the EMBER-3 trial, the combination of Inluriyo and abemaciclib showed a 43% risk reduction in the overall population versus Inluriyo alone.
• Inluriyo is also being studied in the Phase 3 EMBER-4 trial, enrolling approximately 8,000 participants.

Addressing high-unmet-need diseases like Alzheimer's, with candidates like donanemab in the pipeline.

Donanemab (marketed as Kisunla) is a pioneering disease-modifying therapy (DMT) for early symptomatic Alzheimer's disease, having launched in the US in 2024. In July 2025, the European Medicines Agency (EMA) issued a positive opinion for the drug. Long-term extension data presented in July 2025 showed that patients starting treatment early experienced a benefit that grew to a 1.2 point reduction on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 36 months, compared to delayed starters. GlobalData forecasts donanemab sales could reach US$3.8 billion by 2033. Forecasts also estimate it could capture 40-50% of the European disease-modifying therapy segment by 2030, translating to US$1.8-2.25 billion in European sales by that year.

Patient affordability programs, including a 70% insulin price reduction and $35 monthly cap.

Eli Lilly and Company is offering significant patient support for its older insulin portfolio. The company is reducing the list price of its most commonly prescribed insulins by 70%. Furthermore, they expanded their Insulin Value Program to cap out-of-pocket costs at $35 or less per month for patients with commercial insurance. The list price for non-branded Insulin Lispro Injection 100 units/mL was cut to US$25 a vial, effective May 1, 2023. The 70% list price cuts for Humalog and Humulin were effective in Q4 2023.

Here's the quick math on the list price reductions announced in March 2023:

• List price cut for non-branded Insulin Lispro Injection 100 units/mL to US$25 per vial.
• List price cut for Humalog (insulin lispro injection) 100 units/mL by 70%.
• List price cut for Humulin (insulin human) injection 100 units/mL by 70%.
• Launch of Rezvoglar KwikPens at a 78% discount to Lantus.

Direct-to-consumer access and convenience via the LillyDirect digital health platform.

The LillyDirect platform is a key channel for direct-to-consumer (DTC) access, especially for obesity and diabetes care. Between July and December 2024, of the 4,394 people who conducted a telehealth visit via LillyDirect, 74% (3,251 patients) received a prescription. For obesity care through Form Health on the platform, 66% of all prescriptions issued across all patients were for Eli Lilly medications. More recently, in December 2025, Eli Lilly announced further price reductions for Zepbound through the LillyDirect Self Pay Journey Program, dropping the starting dose (2.5 mg) to US$299 a month, which is US$50 less than the previous self-pay price.

Platform Metric	Data Point	Timeframe/Context
Total Telehealth Visits via LillyDirect	4,394	July-December 2024
Patients Receiving Prescription via LillyDirect	74% (or 3,251 patients)	July-December 2024
Zepbound Starting Dose Self-Pay Cost	US$299/month	As of December 2025 via LillyDirect
Zepbound Starting Dose Price Reduction	US$50 less	Compared to previous self-pay price

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Relationships

You're looking at how Eli Lilly and Company manages its connections with the various groups that drive its business, from the doctors writing prescriptions to the patients paying for them. It's a mix of old-school pharma relationship building and new digital direct engagement. Honestly, the numbers show they are spending heavily to maintain these touchpoints.

The engagement with healthcare providers (HCPs) remains a cornerstone. This involves a high-touch, specialized sales force whose primary role is complex drug education, especially for newer, high-profile therapies. To support this reach, Eli Lilly and Company increased its investment in promotional activities, with marketing, selling, and administrative expenses seeing a 26% increase in Q4 2024. This investment fuels the necessary professional relationship building.

Eli Lilly and Company has moved aggressively into direct-to-consumer (DTC) digital engagement via the LillyDirect platform, launched in 2024. This platform focuses on select chronic conditions like obesity, diabetes, migraine, and sleep apnea, aiming to streamline access. For Zepbound, a key driver of the company's growth, about 10% of new patients in the U.S. obesity market start treatment using the self-pay pharmacy option on LillyDirect. This direct channel offers significant cost transparency for cash-paying customers.

Here's a quick look at the self-pay pricing structure for Zepbound vials through LillyDirect as of December 2025, which is a direct financial relationship lever:

Dose (mg)	Self-Pay Price (Monthly)	Previous Price
2.5	$299	$349
5	$399	$499
Higher Doses	$449	$499

Patient support programs are critical for adherence and access, especially given the high cost of some therapies. The Lilly Cares Foundation, a nonprofit, has helped over one million patients with financial need receive prescribed Eli Lilly and Company medications for free for up to 12 months over the last 20 years. Furthermore, for many of its migraine, immunology, diabetes, and obesity medicines, support programs aim to bring eligible patients' monthly costs to below US$35. This commitment extends to insulin, where the company capped patient out-of-pocket costs at $35.

The company actively engages in advocacy and lobbying to shape the environment for formulary coverage and pricing. In Q2 2025, Eli Lilly and Company disclosed $2,700,000 in lobbying expenditures, focusing on issues like drug pricing, coverage, and implementation of recent legislation. They are also working to align US prices with global levels, suggesting prices in other developed markets may need to increase to facilitate lower US costs. Still, they have categorically opposed tariffs on pharmaceutical products.

Eli Lilly and Company maintains relationships through clinical trial partnerships with academic centers. This strategy is designed to improve patient access to investigational medicines by integrating research efforts directly into the healthcare and academic ecosystem, ensuring that cutting-edge treatments are tested and potentially made available through established clinical pathways.

Eli Lilly and Company (LLY) - Canvas Business Model: Channels

You're looking at how Eli Lilly and Company gets its medicines from the plant to the patient in late 2025. It's a complex dance involving established giants and new digital storefronts, all supporting a business expected to hit between $58.0 billion and $61.0 billion in global revenue for the full year 2025.

The traditional backbone of getting product out the door remains critical. Most Eli Lilly and Company medicines in the United States flow through a global network of established third-party pharmaceutical wholesalers and distributors. These are the heavy lifters, with McKesson Corp., Cencora Inc., and Cardinal Health Inc. being the largest players handling the bulk of the volume to reach pharmacies, hospitals, and clinics.

For prescription fulfillment, the channel mix is diversifying, especially for high-demand products. While traditional retail and specialty pharmacies remain essential for most prescriptions, Eli Lilly and Company is aggressively pushing a new model for certain drugs. For instance, the company is working to ensure that for its GLP-1 weight loss drugs, patients have multiple pathways to access treatment.

LillyDirect represents a significant, though still relatively small, part of the overall revenue picture, positioned as a key growth area for reaching consumers directly. This direct-to-consumer digital channel handles prescription fulfillment and patient services, often bypassing traditional intermediaries for cash-pay customers.

Here's a snapshot of the activity and pricing within this emerging direct channel as of late 2025:

Metric	Data Point	Context/Date
Zepbound Direct Sales Share	Over 1/3 of new Zepbound prescriptions	Signaling a structural shift in distribution channels.
Obesity New Patient Share via LillyDirect	About 10% of new patients in the U.S. obesity market	Using LillyDirect's self-pay pharmacy.
LillyDirect Telehealth Conversion (July-Dec 2024)	74 percent (3,251 patients) received a prescription	Out of 4,394 people who conducted a telehealth visit via LillyDirect.
Zepbound 2.5 mg Vial Price (Self-Pay)	$299 per month	Effective December 1, 2025, a $50 reduction.
Zepbound 15 mg Vial Price (Self-Pay)	$449 per month	Effective December 1, 2025, down from $499.

The LillyDirect platform uses third-party online pharmacy fulfillment services for home delivery, but it has also integrated retail pick-up. Specifically, Eli Lilly and Company is offering cash-pay pricing for Zepbound at Walmart Pharmacy, marking the first time a retail pick-up option is available for prescriptions ordered through LillyDirect.

Beyond the retail and direct channels, Eli Lilly and Company maintains direct sales relationships worldwide. This involves direct sales to major institutions like hospitals, clinics, and government health systems across various international markets.

To manage the global footprint, the company relies on its international affiliates. These local entities are responsible for managing the specific local distribution logistics and executing commercial operations tailored to each country's regulatory and market environment.

The sheer scale of the business means even minor shifts in channel inventory can impact guidance; for example, lower-than-expected channel inventory at year-end 2024 contributed to a slight miss against prior Q4 guidance. Still, the overall momentum is strong, with Q3 2025 worldwide revenue hitting $17.60 billion, up 54% year-over-year.

Finance: draft 13-week cash view by Friday.

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Segments

Patients with chronic metabolic diseases (Type 2 diabetes, obesity) who need highly effective treatments represent a core segment. Eli Lilly and Company saw its Q1 2025 revenue surge by 45% YoY to $12.73 billion, heavily driven by this area. Mounjaro (tirzepatide) for Type 2 diabetes contributed $3.84 billion in Q1 2025 revenue, marking a 113% YoY increase. Zepbound (tirzepatide) for obesity generated $2.31 billion in Q1 2025, showing a 345% YoY growth.

Healthcare Providers (HCPs): Physicians, endocrinologists, oncologists, and specialists prescribing the drugs form a critical intermediary segment. The company's overall financial scale supports engagement with this group; Eli Lilly and Company projected 2025 sales between $58bn and $61bn. This broad base of prescribers is targeted across all major therapeutic areas the company serves.

Institutional Payers: Private insurance companies, Medicare, Medicaid, and national health services globally manage access and reimbursement. Eli Lilly and Company struck a deal in November 2025 with the U.S. government to slash prices for Medicare and Medicaid programs. Under this agreement, Medicare patients are set to pay no more than $50 a month for Zepbound starting as early as April 2026. Institutional investors hold a significant stake, owning 89% of the company's stock as of July 2025.

Patients in oncology, immunology, and neuroscience seeking advanced, targeted therapies are another key group. Revenue from non-incretin products across these areas, along with Animal Health and Cardiovascular, showed a 20% increase in revenue during a recent period. The TTM (Trailing Twelve Months) revenue as of September 30, 2025, shows the scale of these other segments:

Segment	TTM Revenue (as of Sep 30, 2025)
Diabetes	$42.84B
Oncology	$9.32B
Immunology	$5.00B
Neuroscience	$1.32B

Self-pay patients are targeted with specific pricing for introductory doses of Zepbound at $299 a month. This price is for the 2.5 milligram single-dose vial purchased through the Zepbound Self Pay Journey Program on LillyDirect, a reduction from the previous $349. The 5 milligram dose is priced at $399 a month, down from $499. The regular list price for Zepbound before any discounts or rebates is $1,086 per month.

Eli Lilly and Company (LLY) - Canvas Business Model: Cost Structure

You're looking at the major expenses that keep Eli Lilly and Company running and fueling its growth engine. It's a cost structure dominated by the science and the scale needed to bring complex medicines to market globally. Honestly, the numbers tell you exactly where the money is going.

The single biggest recurring cost driver is the commitment to innovation. Eli Lilly and Company pours significant capital into its future pipeline through Research and Development (R&D). For the third quarter of 2025 alone, R&D expenses hit $3.47 billion. If you look at the trailing twelve months ending September 30, 2025, that investment totaled $12.558B. This is the price of staying at the forefront of biopharma.

Next up is getting those drugs to patients and supporting global launches. Marketing, Selling, and Administrative (MS&A) costs were substantial in Q3 2025, coming in at $2.74 billion. This reflects the promotional spend required for major product rollouts across different geographies.

The actual production of medicines is another massive cost center. Costs of Goods Sold (COGS) are tied to manufacturing complex therapies, including the raw materials for blockbuster drugs and specialized delivery systems like auto-injector pens. Using the Q3 2025 revenue of $17.60 billion and the reported GAAP Gross Margin of $14.59 billion, we can see the implied COGS for the quarter.

Cost Component (Q3 2025)	Financial Amount
Revenue	$17.60 billion
Gross Margin (GAAP)	$14.59 billion
Implied COGS (GAAP)	$3.01 billion

Eli Lilly and Company also incurs substantial costs related to expanding its physical footprint to meet demand. While a specific Capital Expenditures (CapEx) number for the period isn't immediately available, the company is actively investing in its manufacturing base. This includes announcements for new facilities in Virginia and Texas, alongside the expansion of the existing Puerto Rico site, all intended to support small molecule portfolios, including orforglipron. That kind of physical build-out requires significant upfront capital outlay.

Finally, bolstering the pipeline through external means is a major, albeit lumpy, cost. This shows up as acquisition and licensing charges. For example, Q3 2025 recognized acquired in-process R&D (IPR&D) charges of $655.7 million. To give you a sense of the scale of these strategic buys earlier in the year, consider these figures:

• Acquisition of Scorpion Therapeutics pipeline for up to $2.5 billion.
• Acquisition of SiteOne Therapeutics for as much as $1 billion.
• Acquisition of Verve Therapeutics valued at approximately $1.05 billion.
• Estimated IPR&D charge for Q1 2025 was approximately $1.57 billion pre-tax.

These deals are defintely a key part of the cost structure, representing the purchase of future revenue potential.

Eli Lilly and Company (LLY) - Canvas Business Model: Revenue Streams

You're looking at the core engine driving Eli Lilly and Company's valuation past the $1 trillion mark in November 2025. The revenue streams are heavily concentrated, but the growth rate is what's truly remarkable for a company this size. Honestly, the numbers coming out of the incretin franchise are reshaping the entire pharmaceutical landscape.

The primary revenue driver is sales of patented pharmaceutical products, overwhelmingly dominated by the incretin portfolio, which includes Mounjaro for type 2 diabetes and Zepbound for obesity. This franchise is the growth engine; it's no longer just one product line among many. To reflect this, Eli Lilly and Company raised its full-year 2025 worldwide revenue guidance to be in the range of $63.0 billion to $63.5 billion, up from earlier projections of $58.0 billion to $61.0 billion. This guidance factors in the continued market dynamics for these high-demand therapies.

Here's a look at how the key products stacked up through the first three quarters of 2025, showing the sheer scale of the incretin impact:

Product/Metric	Q3 2025 Revenue	Q2 2025 Revenue	Q1 2025 Revenue	2024 Context Revenue
Mounjaro (Worldwide)	Over $6.5 billion (Q3)	$5.20 billion	$3.84 billion	37% of 2024 revenue (Mounjaro & Zepbound combined)
Zepbound (U.S. Sales)	Part of $10.1 billion combined (Q3)	$3.38 billion (U.S.)	$2.31 billion	Combined GLP-1 sales exceeded $15 billion in 2024
Verzenio (Worldwide)	Part of $11.98 billion (Key Products Total Q3)	$1.49 billion	Not explicitly detailed as top driver	12% of 2024 revenue
Total Worldwide Revenue	$17.60 billion (+54% YoY)	$15.56 billion (+38% YoY)	$12.73 billion (+45% YoY)	$45.04 billion (Full Year 2024)

Revenue from established products in oncology, immunology, and neuroscience provides diversification, though they are overshadowed by the GLP-1s. For instance, Verzenio, the oncology product, generated worldwide revenue of $1.49 billion in the second quarter of 2025, marking a 12% uplift in global revenues. Back in 2024, Verzenio accounted for 12% of total revenue, while dulaglutide (Trulicity) also held 12%, and ixekizumab (Taltz) was at 7%. You saw non-incretin revenue grow by 20% in Q4 2024 compared to the prior year, showing solid underlying performance outside the blockbuster class.

Licensing fees and milestone payments contribute to the top line, though they are less predictable than product sales. Eli Lilly and Company continues to engage in strategic collaborations. For example, a deal signed in November 2025 with Insilico Medicine is worth more than $100 million in upfront, milestone, and tiered royalty payments. Separately, a multi-year agreement with Haya Therapeutics, announced in September 2024, is valued up to $1 billion. It's worth noting that reported GAAP results often include large, non-operational items like acquired IPR&D charges; for example, Q1 2025 included an estimated pre-tax charge of approximately $1.57 billion related to these activities.

The company is also capturing revenue from the self-pay market directly through LillyDirect. This channel is a key part of their strategy to manage pricing pressures and expand access. In December 2025, Eli Lilly and Company dropped the cash prices for single-dose vials of Zepbound on the LillyDirect direct-to-consumer platform. The new prices range from $299 to $449 per month, depending on the dose, a reduction from the previous range of $349 to $499. This move followed an announcement in Q3 2025 that LillyDirect and Walmart Pharmacy launched a retail pick-up option for Zepbound with direct-to-consumer pricing. That's defintely a strategic pricing lever you need to track.